.svg)
Patient Information
Discover the future of your family’s health with Orchid’s Whole Genome Embryo Screening Report
WHAT IS ORCHID?
Orchid overview
Orchid is a cutting-edge whole genome embryo screening that combines Preimplantation Genetic Testing for Aneuploidy (PGT-A), Preimplantation Genetic Testing for Monogenic/Single Gene Defects (PGT-M), and screens for hundreds of genes linked to severe monogenic diseases.
Orchid helps families maximize their chance for a successful pregnancy and healthy baby by screening embryos using whole genome sequencing.
Orchid obtains 100x more data, and reads >99%* of an embryo’s genome (compared to <1% that our competitors read). This is all done using the same 5-6 cell trophectoderm biopsy. With this advanced data, Orchid can detect conditions that other tests miss.
Orchid helps families maximize their chance for a successful pregnancy and healthy baby by screening embryos using whole genome sequencing.
Orchid obtains 100x more data, and reads >99%* of an embryo’s genome (compared to <1% that our competitors read). This is all done using the same 5-6 cell trophectoderm biopsy. With this advanced data, Orchid can detect conditions that other tests miss.
* Percentage is based on validation studies using genomic regions of National Institute of Standards and Technology - GIAB samples
Why is Orchid different?
Comparing Orchid to traditional PGT
Orchid offers several advantages over existing PGT methodologies. These include faster turnaround times, the ability to detect conditions that other tests may miss, and a comprehensive single screen that includes PGT-A, PGT-M, and gene panels. Moreover, Orchid provides one-on-one genetic counseling for all patients at no additional charge.
PGT-A
- 100x more data than traditional PGT-A tests
- Detect triploidy and molar embryos (complete uniparental isodisomy) that other labs might miss
- Detect microdeletions + microduplications screened for during pregnancy but missed in traditional PGT
- Plus all traditional PGT-A features
PGT-M
- No probe design is necessary, which means faster turnaround time and less coordination
- Ideal for:
- Challenging PGT-M cases that may have been denied by other companies
- Patients with a previous pregnancy/child with a de novo variant
- Patients using an egg, sperm, or embryo donor
- Faster results (3 weeks vs. 3 months)
- Patients can screen for hundreds of monogenic diseases simultaneously (through gene panels)
Gene panels
- Screen for hundreds of genetic neurodevelopmental conditions, genetic causes of birth defects, and genes associated with hereditary cancer.
- Includes single gene disorders associated with advancing paternal age
Want to learn more? See our list of screened genes.
Learn MoreParental confirmation
- Saliva-based test to confirm parental relationship to embryos
- Non-blood samples increase convenience and ease for patients
Orchid’s comprehensive screening
Orchid's comprehensive screening combines PGT-A, PGT-M, screens for 100s of genes linked to severe disease, and measures genetic predisposition to disease. These are all screened simultaneously from the same embryo biopsy used in traditional testing.
Detect extra or missing chromosomes
Detect one gene that causes one condition
Detect genetic predisposition (genetic risk scores)
Detect neurodevelopmental disorders (monogenic)
Detect pediatric and adult onset cancers (monogenic)
Detect birth defects (monogenic)
A/SR
PGT
M
P
ORCHID SCIENTIFIC ADVISORS
Developed by world-class experts
The technology behind Orchid has been developed by experts in medical genetics, embryology, and assisted reproductive technology.
%20(1).webp)
Jacques Cohen, PhD
Pioneering Embryologist and foundational figure in IVF and ART innovation
Roohi Jeelani, MD
Double board certified Reproductive Endocrinologist and Infertility Specialist (REI)
Lusine Aghajanova, MD, PhD
Clinical Assistant Professor at the Stanford Medical Center
.webp)
Barry Behr, PhD
Professor of Obstetrics and Gynecology Emeritus at the Stanford Medical Center
%20(1).webp)
Jerry Lanchbury, PhD
Expert in immunogenetics, 100+ peer reviewed publications
.webp)
Jan Liphardt, PhD
Professor of Bioengineering at Stanford University
Nathan Slotnick, MD, PhD
Perinatologist and Medical Geneticist
Amber Cooper, MD
Double board certified Obstetrics and Gynecologist and Reproductive Endocrinologist and Infertility Specialist.
How much does orchid cost?
Resources for financial investment
As the world's first comprehensive whole genome embryo screening solution, Orchid represents a significant advancement in genetic testing for family planning. Our premium service >99% of an embryo's genome, providing unparalleled insight into your future child's health compared to traditional genetic testing methods that only look at <1%.
While our cutting-edge technology and thorough analysis reflect our premium pricing, we understand that building a family is a significant investment. That's why we've partnered with CapexMD to make Orchid more accessible to growing families.
CapexMD specializes in patient financing services for all fertility treatment options. They offer a streamlined financing experience with:
While our cutting-edge technology and thorough analysis reflect our premium pricing, we understand that building a family is a significant investment. That's why we've partnered with CapexMD to make Orchid more accessible to growing families.
CapexMD specializes in patient financing services for all fertility treatment options. They offer a streamlined financing experience with:
- Easy & secure online application process
- Personal attention and concierge-level service to reduce stress
- Flexible payment terms with no membership fees
- No annual fees
- No prepayment penalties
FAQs
What genetic variations are included in Orchid’s
report?
report?
While there can be hundreds of genetic variations within an embryo, Orchid only reports on genes known to cause monogenic disease based on decades of research. Genes included on our panels are selected based on extensive literature searches and information from the Clinical Domain Working Group, a group of independent academic geneticists. Only pathogenic and likely pathogenic variants based on the American College of Medical Genetics and Genomics (ACMG) guidelines are included. Carrier status is not reported unless requested.
Who would benefit most from Orchid?
Any patient could benefit from Orchid, but a few examples of patients that would be most interest/benefit:
- Patients looking to use the most advanced genetic testing option available, or are otherwise concerned about neurodevelopmental disorders, pediatric cancers, and/or birth defects
- Patients who might traditionally do PGT-M (Orchid does not usually require probe development, which increases speed to results)
- Patients concerned about de novo variants (i.e., advanced paternal age, a previous child with a de novo variant)
- Patients using donor egg/sperm/embryos, with potentially limited contact with donor for testing
How much does Orchid cost?
Orchid’s standard Preimplantation Whole-Genome Sequencing costs roughly $12,500 for an IVF cycle with 5 biopsied embryos. However, costs may vary depending on the clinic and the complexity of a case (additional testing may incur additional costs). For cost-sensitive patients, options for more limited screening may be available. For more details please contact genetics@orchidhealth.com.
© 2025 Orchid
